Publications

Search for any of these articles on PubMed

Cancer Epidemiology and Chemoprevention Research Program investigators are indicated in bold; co-authors who are primary members of other NCCC Research Programs are indicated in bold italics.

Abenhaim HA, Titus-Ernstoff L, Cramer DW (2007). Ovarian cancer risk in relation to medical visits, pelvic examinations and type of health care provider. CMAJ 176(7):941-947.

*Adachi-Mejia AM, Dalton MA, Gibson JJ, Beach ML, Titus-Ernstoff LT, Heatherton TF, Sargent JD (2005). Tobacco brand appearances in movies before and after the master settlement agreement. JAMA 293(19):2341-2342.

*Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Titus-Ernstoff L, Skalla K, Bakitas M, Silberfarb PM (2005). Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. J Clin Oncol 23(19):4399-4405.

*Andrew AS, Burgess JL, Meza MM, Demidenko E, Waugh MG, Hamilton JW, Karagas MR (2006). Arsenic exposure is associated with decreased DNA repair in vitro and in individuals exposed to drinking water arsenic. Environ Health Perspect 114(8):1193-1198.

*Andrew AS, Karagas MR, Hamilton JW (2003). Decreased DNA repair gene expression among individuals exposed to arsenic in United States drinking water. Int J Cancer 104(3):263-268.

*Andrew AS, Karagas MR, Nelson HH, Guarrera S, Polidoro S, Gamberini S, Sacerdote C, Moore JH, Kelsey KT, Demidenko E, Vineis P, Matullo G (2008). DNA repair polymorphisms modify bladder cancer risk: A multi-factor analytic strategy. Hum Hered 65(2):105-118.

*Andrew AS, Nelson HH, Kelsey KT, Moore JH, Meng AC, Casella DP, Tosteson TD, Schned AR, Karagas MR (2006). Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. Carcinogenesis 27(5):1030-1037.

*Andrew AS, Schned AR, Heaney JA, Karagas MR (2004). Bladder cancer risk and personal hair dye use. Int J Cancer 109(4):581-586.

*Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, Tice JA, Buist DS, Geller BM, Rosenberg R, Yankaskas BC, Kerlikowske K (2006). Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 98(17):1204-1214.

Baron J, Cole BF, Mott L, Haile R, Grau M, Church TR, Beck GJ, Greenberg ER (2003). Neoplastic and antineoplastic effects of beta-carotene on colorectal adenoma recurrence: Results of a randomized trial. J Natl Cancer Inst 95(10):717-722.

*Baron JA, Beach M, Wallace K, Grau MV, Sandler RS, Mandel JS, Heber D, Greenberg ER (2005). Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomarkers Prev 14(3):586-589.

Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU (2003). A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348(10):891-899.

Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG, Approved Trial Investigators (2006). A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131(6):1674-1682.

Barry EL, Baron JA, Bhat S, Grau MV, Burke CA, Sandler RS, Ahnen DJ, Haile RW, O'Brien TG (2006). Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. J Natl Cancer Inst 98(20):1494-1500.

Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092-1102.

Burrage PS, Huntington JT, Sporn MB, Brinckerhoff CE (2007). Regulation of matrix metalloproteinase gene expression by a retinoid X receptor-specific ligand. Arthritis Rheum 56(3):892-904.

*Carney PA, Goodrich ME, Mackenzie T, Weiss JE, Poplack SP, Wells WS, Titus-Ernstoff L (2005). Utilization of screening mammography in New Hampshire: A population-based assessment. Cancer 104(8):1726-1732.

Celaya MO, Rees JR, Gibson JJ, Riddle BL, Greenberg ER (2006). Travel distance and season of diagnosis affect treatment choices for women with early-stage breast cancer in a predominantly rural population (United States). Cancer Causes Control 17(6):851-856.

*Chapman MS, Spencer SK, Brennick JB (2003). Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol 14(5):943-944.

*Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, Mitsiades C, Munshi N, Tai YT, Suh N, Gribble GW, Honda T, Schlossman R, Richardson P, Sporn MB, Anderson KC (2004). The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 103(8):3158-3166.

*Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, Snover DC, Church TR, Allen JI, Robertson DJ, Beck GJ, Bond JH, Byers T, Mandel JS, Mott LA, Pearson LH, Barry EL, Rees JR, Marcon N, Saibil F, Ueland PM, Greenberg ER (2007). Folic acid for the prevention of colorectal adenomas: A randomized clinical trial. For the Polyp Prevention Study Group. JAMA 297(21):2351-2359.

Colt JS, Baris D, Stewart P, Schned AR, Heaney JA, Mott LA, Silverman D, Karagas M (2004). Occupation and bladder cancer risk in a population-based case-control study in New Hampshire. Cancer Causes Control 15(8):759-769.

*Couch RD, Browning RG, Honda T, Gribble GW, Wright DL, Sporn MB, Anderson AC (2005). Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: Implications for a molecular mechanism of action. Bioorg Med Chem Lett 15(9):2215-2219.

*Couch RD, Ganem NJ, Zhou M, Popov VM, Honda T, Veenstra TD, Sporn MB, Anderson AC (2006). 2-cyano-3,12-dioxooleana-1,9(11)-diene-28-oic acid disrupts microtubule polymerization: A possible mechanism contributing to apoptosis. Mol Pharmacol 69(4):1158-1165.

*Crocenzi TS, Tretter CP, Schwaab T, Schned AR, Heaney JA, Cole BF, Fisher JL, Ernstoff MS (2005). Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients. Clin Immunol 117(1):6-11.

*Dalton MA, Sargent JD, Beach ML, Titus-Ernstoff L, Gibson JJ, Ahrens MB, Tickle JJ, Heatherton TF (2003). Effect of viewing smoking in movies on adolescent smoking initiation: A cohort study. Lancet 362(9380):281-285.

Danaee H, Karagas MR, Kelsey KT, Perry AE, Nelson HH (2006). Allelic loss at Drosophila patched gene is highly prevalent in basal and squamous cell carcinomas of the skin. J Invest Dermatol 126(5):1152-1158.

*Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW, Sporn MB, Talalay P (2005). Extremely potent triterpenoid inducers of the Phase 2 response: Correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A 102(12):4584-4589.

*Dragnev KH, Petty WJ, Dmitrovsky E (2003). Retinoid targets in cancer therapy and chemoprevention. Cancer Biol Ther 2(4 Suppl 1):S150-S156.

*Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, Dmitrovsky E (2005). Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol 23(34):8757-8764.

*Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black CC, Memoli V, Nugent WC, Hermann T, Negro-Vilar A, Rigas JR, Dmitrovsky E (2007). A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res 13(6):1794-1800.

*Dragnev KH, Pitha-Rowe I, Ma Y, Petty WJ, Sekula D, Murphy B, Rendi M, Suh N, Desai NB, Sporn MB, Freemantle SJ, Dmitrovsky E (2004). Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: Implications for combination therapy. Clin Cancer Res 10(7):2570-2577.

*Dragnev KH, Stover D, Dmitrovsky E (2003). Lung cancer prevention: The guidelines. Chest 123(1 Suppl):60S-71S.

Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA (2006). Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 15(4):726-731.

Duell EJ, Holly EA (2005). Reproductive and menstrual risk factors for pancreatic cancer: A population-based study of San Francisco Bay area women. Am J Epidemiol 161(8):741-747.

Egner PA, Yu X, Johnson JK, Nathasingh CK, Groopman JD, Kensler TW, Roebuck BD (2003). Identification of Aflatoxin M(1)-N(7)-Guanine in liver and urine of tree shrews and rats following administration of Aflatoxin B(1). Chem Toxicol 16(9):1174-1180.

*Ernstoff MS, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D, Foster C, Farnham CJ, Mackay K, Szczepiorkowski ZM, Webber SM, Schned AR, Harris RD, Barth RJ, Jr., Heaney JA, Noelle RJ (2007). Developing a rational tumor vaccine therapy for renal cell carcinoma: Immune yin and yang. Clin Cancer Res 13(2 Pt 2):733s-740s.

*Fava RA, Elliott S, Raymond L, Mollmark J, Hays E, Honda T, Gribble GW, Sporn MB, Vincenti MP (2007). The synthetic triterpenoid TP-222 inhibits RANKL stimulation of osteoclastogenesis and matrix metalloproteinase-9 expression. J Rheumatol 34(5):1058-1068.

Feng Q, Sekula D, Muller R, Freemantle SJ, Dmitrovsky E (2007). Uncovering residues that regulate cyclin D1 proteasomal degradation. Oncogene 26(35):5098-5106.

*Fortuny J, Kogevinas M, Zens MS, Schned A, Andrew AS, Heaney J, Kelsey KT, Karagas MR (2007). Analgesic and anti-inflammatory drug use and risk of bladder cancer: A population based case control study. BMC Urol 7:13.

*Freemantle SJ, Dragnev KH, Dmitrovsky E (2006). The retinoic acid paradox in cancer chemoprevention. J Natl Cancer Inst 98(7):426-427.

Freemantle SJ, Liu X, Feng Q, Galimberti F, Blumen S, Sekula D, Kitareewan S, Dragnev KH, Dmitrovsky E (2007). Cyclin degradation for cancer therapy and chemoprevention. J Cell Biochem 102(4):869-877.

*Freemantle SJ, Spinella MJ, Dmitrovsky E (2003). Retinoids in cancer therapy and chemoprevention: Promise meets resistance. Oncogene 22(47):7305-7315.

Gaudet MM, Egan KM, Lissowska J, Newcomb PA, Brinton LA, Titus-Ernstoff L, Yeager M, Chanock S, Welch R, Peplonska B, Trentham-Dietz A, Garcia-Closas M (2007). Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk. Hum Genet 121(3-4):483-490.

*Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VF, Israel MA (2007). Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67(6):2456-2468.

*Grau M, Baron J, Sandler RS, Haile RW, Beach ML, Church TR, Heber D (2003). Vitamin D, calcium supplementation, and colorectal adenomas: Results of a randomized trial. J Nat Cancer Inst 95(23):1765-1771.

Grau MV, Baron JA, Barry EL, Sandler RS, Haile RW, Mandel JS, Cole BF (2005). Interaction of calcium supplementation and nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 14(10):2353-2358.

Grau MV, Baron JA, Langholz B, Karagas M, Greenberg ER, Stukel TA, Mandel JS (2006). Effect of NSAIDs on the recurrence of nonmelanoma skin cancer. Int J Cancer 119(3):682-686.

*Grau MV, Baron JA, Sandler RS, Wallace K, Haile RW, Church TR, Beck GJ, Summers RW, Barry EL, Cole BF, Snover DC, Rothstein R, Mandel JS (2007). Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial. J Natl Cancer Inst 99(2):129-136.

Grau MV, Rees JR, Baron JA (2006). Chemoprevention in gastrointestinal cancers: Current status. Basic Clin Pharmacol Toxicol 98(3):281-287.

Hahn LW, Ritchie MD, Moore JH (2003). Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 19(3):376-382.

*Halter RJ, Hartov A, Heaney JA, Paulsen KD, Schned AR (2007). Electrical impedance spectroscopy of the human prostate. IEEE Trans Biomed Eng 54(7):1321-1327.

*Heim KC, White KA, Deng D, Tomlinson CR, Moore JH, Freemantle SJ, Spinella MJ (2007). Selective repression of retinoic acid target genes by RIP140 during induced tumor cell differentiation of pluripotent human embryonal carcinoma cells. Mol Cancer 6(1):57.

*Hirao S, Hirao T, Marsit CJ, Hirao Y, Schned A, Devi-Ashok T, Nelson HH, Andrew A, Karagas MR, Kelsey KT (2005). Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer. Cancer 104(9):1918-1923.

*Honda T, Favaloro FG, Jr, Janosik T, Honda Y, Suh N, Sporn MB, Gribble GW (2004). Efficient synthesis of (-) - and (+)-tricyclic compounds with enone functionalities in rings A and C: A novel class of orally active anti-inflammatory and cancer chemopreventive agents. Org Biomol Chem 1(24):4384-4391.

*Honda T, Janosik T, Honda Y, Han J, Liby KT, Williams CR, Couch RD, Anderson AC, Sporn MB, Gribble GW (2004). Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets. J Med Chem 47(20):4923-4932.

*Honda T, Liby KT, Su X, Sundararajan C, Honda Y, Suh N, Risingsong R, Williams CR, Royce DB, Sporn MB, Gribble GW (2006). Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A. Bioorg Med Chem Lett 16(24):6306-6309.

*Honda T, Sundararajan C, Yoshizawa H, Su X, Honda Y, Liby KT, Sporn MB, Gribble GW (2007). Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: Highly potent anti-inflammatory and cytoprotective agents. J Med Chem 50(8):1731-1734.

*Ikeda T, Sporn M, Honda T, Gribble GW, Kufe D (2003). The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. Cancer Res 63(17):5551-5558.

Jacobs ET, Jiang R, Alberts DS, Greenberg ER, Gunter EW, Karagas MR, Lanza E, Ratnasinghe L, Reid ME, Schatzkin A, Smith-Warner SA, Wallace K, Martinez ME (2004). Selenium and colorectal adenoma: Results of a pooled analysis. J Natl Cancer Inst 96(22):1669-1675.

Jenkins MA, Hayashi S, O'Shea AM, Burgart LJ, Smyrk TC, Shimizu D, Waring PM, Ruszkiewicz AR, Pollett AF, Redston M, Barker MA, Baron JA, Casey GR, Dowty JG, Giles GG, Limburg P, Newcomb P, Young JP, Walsh MD, Thibodeau SN, Lindor NM, Lemarchand L, Gallinger S, Haile RW, Potter JD, Hopper JL, Jass JR (2007). Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: A population-based study. Gastroenterology 133(1):48-56.

*Karagas MR, Nelson HH, Sehr P, Waterboer T, Stukel TA, Andrew A, Green AC, Bavinck JN, Perry A, Spencer S, Rees JR, Mott LA, Pawlita M (2006). Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 98(6):389-395.

Karagas MR, Nelson HH, Zens MS, Linet M, Stukel TA, Spencer S, Applebaum KM, Mott L, Mabuchi K (2007). Squamous cell and basal cell carcinoma of the skin in relation to radiation therapy and potential modification of risk by sun exposure. Epidemiology 18(6):776-784.

*Karagas MR, Park S, Nelson HH, Andrew AS, Mott L, Schned A, Kelsey KT (2005). Methylenetetrahydrofolate reductase (MTHFR) variants and bladder cancer: A population-based case-control study. Int J Hyg Environ Health 208(5):321-327.

*Karagas MR, Park S, Warren A, Hamilton J, Nelson HH, Mott LA, Kelsey KT (2005). Gender, smoking, glutathione-S-transferase variants and bladder cancer incidence: A population-based study. Cancer Lett 219(1):63-69.

*Karagas MR, Tosteson TD, Morris JS, Demidenko E, Mott LA, Heaney J, Schned A (2004). Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire. Cancer Causes Control 15(5):465-472.

*Karagas MR, Zens MS, Nelson HH, Mabuchi K, Perry AE, Stukel TA, Mott LA, Andrew AS, Applebaum KM, Linet M (2007). Measures of cumulative exposure from a standardized sun exposure history questionnaire: A comparison with histologic assessment of solar skin damage. Am J Epidemiol 165:719-726.

Karagas MR, Zens MS, Stukel TA, Swerdlow AJ, Rosso S, Osterlind A, Mack T, Kirkpatrick C, Holly EA, Green A, Gallagher R, Elwood JM, Armstrong BK (2006). Pregnancy history and incidence of melanoma in women: A pooled analysis. Cancer Causes Control 17(1):11-19.

*Kelsey KT, Hirao T, Hirao S, Devi-Ashok T, Andrew A, Nelson HH, Colt J, Baris D, Morris JS, Schned A, Karagas M (2005). TP53 alterations and patterns of carcinogen exposure in a U.S. population-based study of bladder cancer. Int J Cancer 117(3):370-375.

*Kelsey KT, Hirao T, Schned A, Hirao S, Devi-Ashok T, Nelson HH, Andrew A, Karagas MR (2004). A population-based study of immunohistochemical detection of p53 alteration in bladder cancer. Br J Cancer 90(8):1572-1576.

Kim S, Baron JA, Mott LA, Burke CA, Church TR, McKeown-Eyssen GE, Cole BF, Haile RW, Sandler RS (2006). Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States). Cancer Causes Control 17(10):1299-1304.

*Kitareewan S, Roebuck BD, Demidenko E, Sloboda RD, Dmitrovsky E (2007). Lysosomes and trivalent arsenic treatment in acute promyelocytic leukemia. J Natl Cancer Inst 99(1):41-52.

*Kittiniyom K, Mastronardi M, Roemer M, Wells WA, Greenberg ER, Titus-Ernstoff L, Newsham IF (2004). Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation. Genes Chromosomes Cancer 40(3):190-203.

Leong NM, Mignone LI, Newcomb PA, Titus-Ernstoff L, Baron JA, Trentham-Dietz A, Stampfer MJ, Willett WC, Egan KM (2003). Early life risk factors in cancer: The relation of birth weight to adult obesity. Int J Cancer 103(6):789-791.

*Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A, Sporn MB (2005). The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 65(11):4789-4798.

*Liby K, Honda T, Williams CR, Risingsong R, Royce DB, Suh N, Dinkova-Kostova AT, Stephenson KK, Talalay P, Sundararajan C, Gribble GW, Sporn MB (2007). Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities. Mol Cancer Ther 6(7):2113-2139.

*Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, Gribble GW, Dmitrovsky E, Sporn TA, Sporn MB (2007). The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res 67(6):2414-2419.

*Liby K, Voong N, Williams CR, Risingsong R, Royce DB, Honda T, Gribble GW, Sporn MB, Letterio JJ (2006). The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 12(14):4288-4293.

Liu JY, Woloshin S, Laycock WS, Rothstein RI, Finlayson SR, SchwartzLM (2004). Symptoms and treatment burden of gastroesophageal reflux disease: Validating the GERD Assessment Scales. Arch Intern Med 164(18):2058-2064.

Ma Y, Feng Q, Sekula D, Diehl JA, Freemantle SJ, Dmitrovsky E (2005). Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms. Cancer Res 65(14):6476-6483.

*Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, Robbins DJ, Bentley HA, Tsongalis GJ, Demidenko E, Freemantle SJ, Dmitrovsky E (2007). Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A 104(10):4089-4094.

*Ma Y, Koza-Taylor PH, DiMattia DA, Hames L, Fu H, Dragnev K, Turi T, Beebe JS, Freemantle SJ, Dmitrovsky E (2003). Microarray analysis uncovers retinoid targets in human bronchial epithelial cells. Oncogene 22:4924-4932.

Madlensky L, Daftary D, Burnett T, Harmon P, Jenkins M, Maskiell J, Nigon S, Phillips K, Templeton A, Limburg PJ, Haile RW, Potter JD, Gallinger S, Baron JA (2007). Accuracy of colorectal polyp self-reports: Findings from the Colon Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 16(9):1898-1901.

Marehbian J, Colt JS, Baris D, Stewart P, Stukel TA, Spencer SK, Karagas MR (2007). Occupation and keratinocyte cancer risk: A population-based case-control study. Cancer Causes Control 18(8):895-908.
Marsit CJ, Houseman EA, Schned AR, Karagas MR, Kelsey KT (2007). Promoter hypermethylation is associated with current smoking, age, gender, and survival in bladder cancer. Carcinogenesis 28(8):1745-1751.

*Marsit CJ, Karagas MR, Andrew A, Liu M, Danaee H, Schned AR, Nelson HH, Kelsey KT (2005). Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res 65(16):7081-7085.

*Marsit CJ, Karagas MR, Danaee H, Liu M, Andrew A, Schned A, Nelson HH, Kelsey KT (2006). Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis 27(1):112-116.

Marsit CJ, Karagas MR, Schned A, Kelsey KT (2006). Carcinogen exposure and epigenetic silencing in bladder cancer. Ann N Y Acad Sci 1076:810-821.

*Mix KS, Coon CI, Rosen ED, Suh N, Sporn MB, Brinckerhoff CE (2004). Peroxisome proliferator-activated receptor-gamma-independent repression of collagenase gene expression by 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and prostaglandin 15-deoxy-delta(12,14) J2: A role for Smad signaling. Mol Pharmacol 65(2):309-318.

Moore JH, Boczko EM, Summar ML (2005). Connecting the dots between genes, biochemistry, and disease susceptibility: Systems biology modeling in human genetics. Mol Genet Metab 84(2):104-111.

Moore JH, Ritchie MD (2004). STUDENTJAMA. The challenges of whole-genome approaches to common diseases. JAMA 291(13):1642-1643.

Olsen CM, Green AC, Zens MS, Stukel TA, Bataille V, Berwick M, Elwood JM, Gallagher R, Holly EA, Kirkpatrick C, Mack T, Osterlind A, Rosso S, Swerdlow AJ, Karagas MR (2007). Anthropometric factors and risk of melanoma in women: A pooled analysis. Int J Cancer 122(5):1100-1108.

Onega T, Baron J, MacKenzie T (2006). Cancer after total joint arthroplasty: A meta-analysis. Cancer Epidemiol Biomarkers Prev 15(8):1532-1537.

Orner GA, Roebuck BD, Dashwood RH, Bailey GS (2006). Post-initiation chlorophyllin exposure does not modulate aflatoxin-induced foci in the liver and colon of rats. J Carcinog 5(1):6.

Palmer JR, Wise LA, Hatch EE, Troisi R, Titus-Ernstoff L, Strohsnitter W, Kaufman R, Herbst AL, Noller KL, Hyer M, Hoover RN (2006). Prenatal diethylstilbestrol exposure and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15(8):1509-1514.

Patel AS, Karagas MR, Perry AE, Spencer SK, Nelson HH (2007). Gene-drug interaction at the glucocorticoid receptor increases risk of squamous cell skin cancer. J Invest Dermatol 127(8):1868-1870.

Pedersen IM, Zapata JM, Samuel T, Scott FL, Salvesen GS, Honda T, Gribble GW, Suh N, Sporn MB, Kipps TJ, Reed JC (2004). Retraction: The triterpenoid CDDO-Imidazolide induces apoptosis and enhances fludarabine-induced apoptosis of CLL B-cells. Blood 104(4):932.

*Petty WJ, Dragnev KH, Memoli VA, Ma Y, Desai NB, Biddle A, Davis TH, Nugent WC, Memoli N, Hamilton M, Iwata KK, Rigas JR, Dmitrovsky E (2004). Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res 10(22):7547-7554.

*Petty WJ, Li N, Biddle A, Bounds R, Nitkin C, Ma Y, Dragnev KH, Freemantle SJ, Dmitrovsky E (2005). A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. J Natl Cancer Inst 97(22):1645-1651.

*Pitha-Rowe I, Petty WJ, Feng Q, Koza-Taylor PH, Dimattia DA, Pinder L, Dragnev KH, Memoli N, Memoli V, Turi T, Beebe J, Kitareewan S, Dmitrovsky E (2004). Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res 64(21):8109-8115.

Pitha-Rowe IF, Hassel BA, Dmitrovsky E (2004). Involvement of UBE1L in ISG15 conjugation during retinoid induced differentiation of acute promyelocytic leukemia. J Biol Chem 279:18178-18187.

*Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, Gribble GW, Leesnitzer LM, Stimmel JB, Willson TM, Rosen E, Sporn MB (2003). The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 9(7):2798-2806.

*Poplack SP, Carney PA, Weiss JE, Titus-Ernstoff L, Goodrich ME, Tosteson AN (2005). Screening mammography: Costs and use of screening-related services. Radiology 234(1):79-85.

Rees JR, Stukel TA, Perry AE, Zens MS, Spencer SK, Karagas MR (2007). Tea consumption and basal cell and squamous cell skin cancer: Results of a case-control study. J Am Acad Dermatol 56(5):781-785.

Reif DM, Dudek SM, Shaffer CM, Wang J, Moore JH (2005). Exploratory visual analysis of pharmacogenomic results. Pac Symp Biocomput:296-307.

*Reif DM, Israel MA, Moore JH (2007, In press). Exploratory visual analysis of statistical results from microarray experiments comparing high and low grade glioma. Cancer Informatics.

Reif DM, Moore JH (2006). Visual analysis of statistical results from microarray studies of human breast cancer. Oncol Rep 15(4):1043-1047.

*Rigas JR, Dragnev KH (2005). Emerging role of rexinoids in non-small cell lung cancer: Focus on bexarotene. Oncologist 10(1):22-33.

Ritchie MD, Hahn LW, Moore JH (2003). Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 24(2):150-157.

Robertson DJ, Burke CA, Schwender BJ, Wargovich MJ, Greenberg ER, Sandler RS, Ahnen DJ, Rothstein R, Mott LA, Baron JA (2005). Histamine receptor antagonists and incident colorectal adenomas. Aliment Pharmacol Ther 22(2):123-128.

*Robertson DJ, Greenberg ER, Beach M, Sandler RS, Ahnen D, Haile RW, Burke CA, Snover DC, Bresalier RS, McKeown-Eyssen G, Mandel JS, Bond JH, Van Stolk RU, Summers RW, Rothstein R, Church TR, Cole BF, Byers T, Mott L, Baron JA (2005). Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology 129(1):34-41.

Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sorensen HT (2007). Proton pump inhibitor use and risk of colorectal cancer: A population-based case-control study. Gastroenterology 133(3):755-760.

*Robertson DJ, Sandler RS, Haile R, Tosteson TD, Greenberg ER, Grau M, Baron JA (2005). Fat, fiber, meat and the risk of colorectal adenomas. Am J Gastroenterol 100(12):2789-2795.

Roebuck BD (2004). Hyperplasia, partial hepatectomy, and the carcinogenicity of aflatoxin B1. J Cell Biochem 91(2):243-249.

Roebuck BD, Curphy TJ, Li Y, Baumgartner KJ, Bodreddigar S, Yan J, Gange SJ, Kensler TW, Sutter TR (2003). Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz. Carcinogenesis 24(12):1919-1928.

*Samudio I, Konopleva M, Hail N, Jr., Shi YX, McQueen T, Hsu T, Evans R, Honda T, Gribble GW, Sporn M, Gilbert HF, Safe S, Andreeff M (2005). 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer. J Biol Chem 280(43):36273-36282.

*Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli NJ, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R (2003). A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348(10):883-890.

*Sargent JD, Beach ML, Adachi-Mejia AM, Gibson JJ, Titus-Ernstoff LT, Carusi CP, Swain SD, Heatherton TF, Dalton MA (2005). Exposure to movie smoking: Its relation to smoking initiation among US adolescents. Pediatrics 116(5):1183-1191.

*Schned AR, Andrew AS, Marsit CJ, Zens MS, Kelsey KT, Karagas MR (2007). Survival following the diagnosis of noninvasive bladder cancer: WHO/International Society of Urological Pathology versus WHO Classification Systems. J Urol 178(4):1196-1200.

*Schwaab T, Tretter CP, Gibson JJ, Cole BF, Schned AR, Harris R, Fisher JL, Crosby N, Stempkowski LM, Heaney JA, Ernstoff MS (2006). Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF). Prostate 66(6):667-674.

*Schwaab T, Tretter CP, Gibson JJ, Cole BF, Schned AR, Harris R, Wallen EM, Fisher JL, Waugh MG, Truman D, Stempkowski LM, Crosby NA, Heaney JA, Ernstoff MS (2004). Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma. J Urol 171(3):1036-1042.

*Shi X, Duell E, Demidenko E, Onega T, Wilson B, Hoftiezer D (2007). A polygon-based locally-weighted-average method for smoothing disease rates of small units. Epidemiology 18(5):523-528.

Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR (2004). Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: A population-based cohort study. J Natl Cancer Inst 96(9):709-711.

Sorensen HT, Mellemkjaer L, Skriver MV, Johnsen SP, Norgard B, Olsen JH, Baron JA (2005). Fever of unknown origin and cancer: A population-based study. Lancet Oncol 6(11):851-855.

Sprague BL, Trentham-Dietz A, Newcomb PA, Titus-Ernstoff L, Hampton JM, Egan KM (2007). Lifetime recreational and occupational physical activity and risk of in situ and invasive breast cancer. Cancer Epidemiol Biomarkers Prev 16(2):236-243.

*Suh N, Roberts AB, Birkey Reffey S, Miyazono K, Itoh S, ten Dijke P, Heiss EH, Place AE, Risingsong R, Williams CR, Honda T, Gribble GW, Sporn MB (2003). Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Res 63(6):1371-1376.

Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC, Cramer DW (2005). Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res 65(13):5974-5981.

Terry KL, Titus-Ernstoff L, McKolanis JR, Welch WR, Finn OJ, Cramer DW (2007). Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 16(1):30-35.

Titus-Ernstoff L, Dalton MA, Adachi-Mejia AM, Longacre MR, Beach ML (2007, In press). A longitudinal study of viewing smoking in movies and smoking initiation in children. Pediatrics.

*Titus-Ernstoff L, Ding J, Perry AE, Spencer SK, Cole BF, Ernstoff MS (2007). Factors associated with atypical moles in New Hampshire, USA. Acta Derm Venereol 87(1):43-48.

*Titus-Ernstoff L, Perry AE, Spencer SK, Gibson J, Ding J, Cole B, Ernstoff MS (2006). Multiple primary melanoma: Two-year results from a population-based study. Arch Dermatol 142(4):433-438.

*Titus-Ernstoff L, Perry AE, Spencer SK, Gibson JJ, Cole BF, Ernstoff MS (2005). Pigmentary characteristics and moles in relation to melanoma risk. Int J Cancer 116:144-149.

Titus-Ernstoff L, Troisi R, Hatch EE, Hyer M, Wise LA, Palmer JR, Kaufman R, Adam E, Noller K, Herbst AL, Strohsnitter W, Cole BF, Hartge P, Hoover RN (2007, In press). Benign and malignant pathology in offspring of women exposedin utero to diethylstilbestrol (DES): A preliminary report of the third generation. Epidemiology.

Titus-Ernstoff L, Troisi R, Hatch EE, Wise LA, Palmer J, Hyer M, Kaufman R, Adam E, Strohsnitter W, Noller K, Herbst AL, Gibson-Chambers J, Hartge P, Hoover RN (2006). Menstrual and reproductive characteristics of women whose mothers were exposed in utero to diethylstilbestrol (DES). Int J Epidemiol 35(4):862-868.

*Tosteson TD, Buzas JS, Demidenko E, Karagas M (2003). Power and sample size calculations for generalized regression models with covariate measurement error. Statist Med 22:1069-1082.

Troisi R, Hatch EE, Titus-Ernstoff L, Hyer M, Palmer JR, Robboy SJ, Strohsnitter WC, Kaufman R, Herbst AL, Hoover RN (2007). Cancer risk in women prenatally exposed to diethylstilbestrol. Int J Cancer 121(2):356-360.

Troisi R, Hatch EE, Titus-Ernstoff L, Palmer JR, Hyer M, Strohsnitter WC, Robboy SJ, Kaufman R, Herbst A, Adam E, Hoover RN (2006). Birth weight and breast cancer risk. Br J Cancer 94(11):1734-1737.

Vinikoor LC, Robertson DJ, Baron JA, Silverman WB, Sandler RS (2007). Cholecystectomy and the risk of recurrent colorectal adenomas. Cancer Epidemiol Biomarkers Prev 16(7):1523-1525.

*Wallace K, Baron JA, Cole BF, Sandler RS, Karagas MR, Beach MA, Haile RW, Burke CA, Pearson LH, Mandel JS, Rothstein R, Snover DC (2004). Effect of calcium supplementation on the risk of large bowel polyps. J Natl Cancer Inst 96(12):921-925.

Wallace K, Baron JA, Karagas MR, Cole BF, Byers T, Beach MA, Pearson LH, Burke CA, Silverman WB, Sandler RS (2005). The association of physical activity and body mass index with the risk of large bowel polyps. Cancer Epidemiol Biomarkers Prev 14(9):2082-2086.

Wallace K, Byers T, Morris JS, Cole BF, Greenberg ER, Baron JA, Gudino A, Spate V, Karagas MR (2003). Prediagnostic serum selenium concentration and the risk of recurrent colorectal adenoma: A nested case-control study. Cancer Epidemiol Biomarkers Prev 12(5):464-467.

Wilke RA, Reif DM, Moore JH (2005). Combinatorial pharmacogenetics. Nat Rev Drug Discov 4(11):911-918.

*Yates MS, Kwak MK, Egner PA, Groopman JD, Bodreddigari S, Sutter TR, Baumgartner KJ, Roebuck BD, Liby KT, Yore MM, Honda T, Gribble GW, Sporn MB, Kensler TW (2006). Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Cancer Res 66(4):2488-2494.

*Yore MM, Liby KT, Honda T, Gribble GW, Sporn MB (2006). The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-{kappa}B activation through direct inhibition of I{kappa}B kinase {beta}. Mol Cancer Ther 5(12):3232-3239.